%0 Journal Article
%T Management of primary Sj£¿gren¡¯s syndrome: recent developments and new classification criteria
%A Claudio Vitali
%A Nicoletta Del Papa
%J Archive of "Therapeutic Advances in Musculoskeletal Disease".
%D 2018
%R 10.1177/1759720X17746319
%X For many years primary Sj£¿gren¡¯s syndrome (pSS) has been considered an orphan disease, since no specific therapies were recognized as being capable of contrasting the development and progression of this disorder. The treatment of oral and ocular features, as well as of the systemic organ involvement, has been entrusted to the joint management of different subspecialty physicians, like ophthalmologists, otolaryngologists, dentists and rheumatologists. These latter subspecialty doctors are usually more involved in the treatment of systemic extraglandular involvement and, to do it, they have long been using the conventional therapies borrowed by the treatment schedules adopted in other systemic autoimmune diseases. The increasing knowledge of the biological pathways that are operative in patients with pSS, and the parallel development of molecular biology technology, have allowed the production and availability of a number of biological agents able to positively act on different disease mechanisms, and thus are candidates for testing in therapeutic trials. Meanwhile, the scientific community has made a great effort to develop new accurate and validated classification criteria and outcome measures to be applied in the selection of patients to be included and monitored in therapeutic studies
%K Sj£¿gren¡¯s syndrome
%K clinical subsetting
%K classification criteria
%K outcome measures
%K pathogenetic mechanisms
%K biological therapies
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784475/